Skip to navigation Skip to content

Clinical Trial: Motor Neuroprosthesis to restore motor control in people with severe impairment to both arms and legs


Treatment mode of action: To improve functional independence
Number of Subjects: 6
Medication: The Synchron Motor NeuroProsthesis, a brain-computer interface
Location: New Jersey|New York|Pennsylvania
Institutions: Mount Sinai (West location)
1000 10th Ave, New York, NY 10019
  Contact Information
Please see below for contact information.


NIH Grant and Sponsor Funded


The Synchron Motor NeuroProsthesis (MNP) is a brain-computer interface intended to improve functional independence and communication of healthcare needs for people who have impaired ability to move their arms and legs. This new device and surgical technique has been developed to record brain signals without the need for open brain surgery. This is an investigational device that uses a thin wire with a stent placed in a blood vessel of the brain. The intention is that signals from the brain will be decoded to enable people to control personal computers, to improve functional independence and communication of healthcare needs. The purpose of this research study is to investigate the safety of using an implanted device called the Stentrode™ to control a computer by thought.

  • Between 21 and 75 years of age
  • Severe impairment to both arms and legs
  • Able to have an MRI scan and undergo anesthesia
  • Fluent in English
  • Study partner/caregiver who is willing to provide support during study
  • Able and willing to access clinical testing sites
The time commitment for this trial involves up to 90 days pre implant, the implant itself (approximately 48 hours) and 12 months post implant. During these periods, there will regular appointments conducted by the researchers. Most can occur at home, while a few need to occur at the hospital. Some appointments involve blood tests or scans, such as an MRI or CT scan.

For further information, please contact: Aidan Rogers or Abbey Sawyer
Email: or

COMMAND Early Feasibility Study: Implantable BCI to Control a Digital Device for People With Paralysis - Full Text View -


© 2024 The National Multiple Sclerosis Society is a tax exempt 501(c)3 nonprofit organization. Its Identification Number (EIN) is 13-5661935.